Japanese drugmaker Ono (TYO: 4528) has entered into a license agreement with USA-based Ionis Pharmaceuticals (Nasdaq: IONS) ...
Ionis will receive $280 million upfront and could get up to $660 million in future milestone payments. Ono will take charge ...
Per the deal terms, IONS will receive an upfront payment of $280 million from Ono. It is also eligible for milestone payments of up to $660 million.
Ionis’ drug, called sapablursen, is currently being tested in a Phase 2 trial in people with polycythemia vera.
Japan's Ono Pharmaceutical is handing over $280 million upfront to acquire Ionis Pharmaceuticals’ phase 2-stage antisense ...
Ono Pharmaceutical Co. Ltd. struck a licensing deal with Ionis Pharmaceuticals Inc. for sapablursen, which is in phase II trials for polycythemia vera. Under terms, Osaka, Japan-based Ono gains an ...
Ionis Pharmaceuticals (IONS) and Ono Pharmaceutical announced that the two companies have entered into a license agreement in which Ono obtains ...
Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) and Ono Pharmaceutical Co., Ltd (Ono), today announced that the two companies have ...
Protagonist Therapeutics, Inc.'s VERIFY and ANTHEM-UC studies show breakthroughs in polycythemia vera and ulcerative colitis.
Truist raised the firm’s price target on Protagonist Therapeutics (PTGX) to $76 from $60 and keeps a Buy rating on the shares. The firm cites ...
A panelist discusses how patient-reported outcomes have transformed their ability to deliver more personalized care ...
A panelist discusses how advances in JAK2 V617F and other molecular monitoring have enhanced their ability to assess ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results